Ebos Group (ASX:EBO) Moat Score: 6/10 (As of Jul. 01, 2026)


ASX:EBO Ebos Group Ltd ASX:EBO
77 GF Score
Price A$17.18
GF Value A$32.93
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Ebos Group Moat Score?

Ebos Group ASX:EBO +0.64% 77 Moat Score is 6 as of Jul. 01, 2026. GuruFocus rates ASX:EBO with a GF Score™ of 77/100 and a GF Value™ of A$32.93 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 119 Medical Distribution companies, Ebos Group ranks better than 97.48% on this metric.

Ebos Group has the Moat Score of 6, which implies that the company might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Ebos Group has Narrow Moat: Ebos Group Ltd has a strong narrow moat due to its leading market position in healthcare and animal care distribution in Australasia. It benefits from economies of scale and a robust distribution network. However, it lacks significant network effects or unique intellectual property that would elevate it to a wide moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Ebos Group might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Ebos Group  (ASX:EBO) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Ebos Group Moat Score Related Terms

ASX:EBO vs MCK, CAH, COR: Moat Score Comparison

For the Medical Distribution subindustry, Ebos Group's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ebos Group Moat Score vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Ebos Group's Moat Score distribution charts can be found below:

* The bar in red indicates where Ebos Group's Moat Score falls into.


ASX:EBO
77GF Score
Ebos Group Ltd ASX:EBO
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 6 mean?
Ebos Group (ASX:EBO) has a Moat Score of 6 as of Jul. 01, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Ebos Group ranks #3 out of 119 companies in the Medical Distribution industry, placing it in the top 2.5%.
Is Ebos Group's Moat Score too high?
Ebos Group's current Moat Score is 6. Based on the distribution chart, Ebos Group ranks #3 out of 119 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Ebos Group has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ebos Group's Moat Score compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Ebos Group ranks #3 out of 119 companies for Moat Score. This places Ebos Group in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Distribution company?
A good Moat Score depends on the Medical Distribution industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Ebos Group's current Moat Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ebos Group stock overvalued right now?
Based on GuruFocus' analysis, Ebos Group (ASX:EBO) is currently considered Significantly Undervalued. The stock's GF Value™ is A$32.93, compared to a current price of A$17.18 — trading 47.8% below its estimated fair value. The current Moat Score is 6. Ebos Group's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Ebos Group (ASX:EBO), the current Moat Score is 6 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ebos Group (ASX:EBO) Overvalued in 2026?

Based on GuruFocus' analysis, Ebos Group stock appears to be undervalued. The current stock price of A$17.18 is trading 47.8% below its estimated GF Value™ of A$32.93. GuruFocus considers Ebos Group to be Significantly Undervalued.

Key valuation signals for ASX:EBO:

  • Moat Score: 6
  • GF Value™: A$32.93 vs. price of A$17.18 (47.8% below fair value)
  • GF Score™: 77/100 with 4 warning signs

No single metric tells the full story. See the ASX:EBO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ebos Group Business Description

Address 737 Bourke Street, Level 7, Docklands, Melbourne, VIC, AUS, 3008
Ebos is the largest pharmaceutical wholesaler across Australia and New Zealand. It services community pharmacies and hospitals, which contribute around 50% and 30% of revenue, respectively. Drug pricing and wholesale margins for PBS medicine are governed by the Australian government's Pharmaceutical Benefits Scheme, or PBS. Wholesale gross margins are capped at 7% for community pharmacy and 10% for hospitals, and ongoing price reform typically results in low-single-digit revenue growth. Aside from pharma distribution, Ebos operates an animal health product wholesale, manufacturing and retail business, as well as undertaking third party logistics services. These segments are smaller contributors to group revenue but due to the unregulated nature are higher-margin operations.
77GF Score

Get the complete analysis for ASX:EBO

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$17.18
Price
A$32.93
GF Value